ABCL
AbCellera Biologics, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$12.63
−0.79%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$12.75
From 52W high−0.79%
Volume5.42M
Market cap$4.09B
P/E (TTM)—
P/S (TTM)61.8x
Div yield—
Key dataSep 18, 2026
Open
$12.75
From 52W high
−0.79%
Volume
5.42M
Market cap
$4.09B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−23.0x
P/E (TTM)
—
RSI (14)
64.8
MomentumView details →
1D Return
−0.79%
YTD Return
+264.77%
SummaryUpdated Jun 1, 2026
AbCellera Biologics Inc. (NASDAQ:ABCL) is a Canadian biotechnology company founded in 2012 and headquartered in Vancouver, Canada. The company went public in December 2020 during the height of the COVID-19 pandemic, largely driven by its successful collaboration with Eli Lilly to develop bebtelovimab, a COVID-19 antibody treatment. AbCellera has since transitioned from primarily being a platform and partnership company to becoming a clinical-stage biotechnology company focused on developing its own pipeline of antibody therapeutics while maintaining selective strategic partnerships.
Similar companies
Latest newsMore news →